These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15544522)

  • 21. Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy.
    Kobori H; Kamiyama M; Harrison-Bernard LM; Navar LG
    J Investig Med; 2013 Feb; 61(2):256-64. PubMed ID: 23266706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of local and systemic angiotensin in diabetic renal disease.
    Anderson S
    Kidney Int Suppl; 1997 Dec; 63():S107-10. PubMed ID: 9407435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of AGEs in diabetic nephropathy.
    Fukami K; Yamagishi S; Ueda S; Okuda S
    Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes.
    Sochett EB; Cherney DZ; Curtis JR; Dekker MG; Scholey JW; Miller JA
    J Am Soc Nephrol; 2006 Jun; 17(6):1703-9. PubMed ID: 16672313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat.
    Kelly DJ; Skinner SL; Gilbert RE; Cox AJ; Cooper ME; Wilkinson-Berka JL
    Kidney Int; 2000 May; 57(5):1882-94. PubMed ID: 10792607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
    Ahmed SB; Hovind P; Parving HH; Rossing P; Price DA; Laffel LM; Lansang MC; Stevanovic R; Fisher ND; Hollenberg NK
    Diabetes Care; 2005 Aug; 28(8):1988-94. PubMed ID: 16043743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.
    Huang XR; Chen WY; Truong LD; Lan HY
    J Am Soc Nephrol; 2003 Jul; 14(7):1738-47. PubMed ID: 12819233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy.
    Rincon-Choles H; Kasinath BS; Gorin Y; Abboud HE
    Kidney Int Suppl; 2002 Dec; (82):S8-11. PubMed ID: 12410848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.
    Cooper ME
    Diabetologia; 2001 Nov; 44(11):1957-72. PubMed ID: 11719827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptors and development: the kidney.
    Alcorn D; McCausland JE; Maric C
    Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S88-92. PubMed ID: 21143279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis.
    Graciano ML; Cavaglieri Rde C; Dellê H; Dominguez WV; Casarini DE; Malheiros DM; Noronha IL
    J Am Soc Nephrol; 2004 Jul; 15(7):1805-15. PubMed ID: 15213268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.
    Zhang Z; Zhang Y; Ning G; Deb DK; Kong J; Li YC
    Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15896-901. PubMed ID: 18838678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of renal renin-angiotensin system in mouse diabetic nephropathy.
    Tamura J; Konno A; Hashimoto Y; Kon Y
    Jpn J Vet Res; 2005 Aug; 53(1-2):13-26. PubMed ID: 16190318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.